Premium
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 ( CYP2C19 ) Genotype and Clopidogrel Therapy
Author(s) -
Scott SA,
Sangkuhl K,
Gardner EE,
Stein CM,
Hulot JS,
Johnson JA,
Roden DM,
Klein TE,
Shuldiner AR
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.132
Subject(s) - cyp2c19 , clopidogrel , medicine , percutaneous coronary intervention , pharmacogenetics , prodrug , clinical pharmacology , conventional pci , pharmacology , adverse effect , genotype , cardiology , cytochrome p450 , myocardial infarction , genetics , biology , metabolism , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom